<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541254</url>
  </required_header>
  <id_info>
    <org_study_id>G110014</org_study_id>
    <nct_id>NCT01541254</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device</brief_title>
  <acronym>LVIS</acronym>
  <official_title>A Feasibility Study of the MicroVention,Inc.(LVIS™) Neurovascular Self-Expanding Retrievable Stent System in the Treatment of Wide-Necked Intracranial Artery Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Microvention-Terumo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and probable benefit of the Low-profile
      Visualized Intraluminal Support (LVIS™ and LVIS™ Jr.)devices from MicroVention, Inc. when
      used to facilitate endovascular coiling of unruptured wide-neck intracranial aneurysms with
      bare platinum embolization coils.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the stent-assisted technique to treat wide neck intracranial aneurysms, the
      neurovascular stent is placed across the aneurysm neck, to act as a bridge to prevent coils
      from protruding into the parent artery. Stenting may allow to more safely achieve a higher
      packing density of coils. These effects may improve the rates of complete aneurysm occlusion
      and enhance the durability of the coiling treatment.The LVIS™ device manufactured by
      MicroVention, Inc. has a braided design which may provide superior conformability and parent
      artery apposition, as well as a more reliable continuous and uniform neck bridging than other
      neurovascular stents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks)</measure>
    <time_frame>6 months ± 4 weeks</time_frame>
    <description>Imaging from each subject to be reviewed by an independent core lab who will be comparing with baseline and post procedure images.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Measures as Any Major Stroke or Death Within 30 Days, or Major Ipsi-lateral Stroke or Neurological Death Within 6 Months</measure>
    <time_frame>30 days-6 months</time_frame>
    <description>A major stroke is defined as a new neurological event that persists for &gt;24 hours and results in a ≥ 4 point increase in the National Institutes of Health Stroke Scale (NIHSS) score compared to baseline or compared to any subsequent lower score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parent Artery Patency Measured Angiographically at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>To be assessed by Independent Core Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful Delivery of the LVIS™ Device Measures by Technical Success</measure>
    <time_frame>24 hours</time_frame>
    <description>Technical success being defined as: access to the lesion, successful deployment of the LVIS™ device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant Stenosis(&gt;50%) of the Treated Artery at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Parent Artery will be measured baseline and compared at 6 months post procedure per review by the Independent Core Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Migration at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Angiographic images will be comparing post procedure sent position to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device and Procedure Related Serious Adverse Events</measure>
    <time_frame>Day 1-6months(± 4 months)</time_frame>
    <description>All Serious Adverse events will be reported per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Embolization Coiling Within 6 Months</measure>
    <time_frame>Day 1-6 months</time_frame>
    <description>If the target lesion(aneurysm)treated needed further embolization within 6 months of initial treatment(detected during follow up or unscheduled visit ),data will be recorded and analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Intracranial Aneurysms</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</intervention_name>
    <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Low-profile Vizualized Intraluminal Support Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject whose age is between 18 and 80 years old

          -  Subject with unruptured wide neck, saccular,intracranial aneurysm, &lt; 20mm maximum
             diameter in any plane ( wide neck defined as neck width ≥ 4mm or dome to-neck ratio &lt;
             2).

          -  Subject's aneurysm arises from a parent vessel with a diameter of ≥ 2.5m and ≤ 4.5mm.

          -  Subject or his/her legally authorized representative understands the nature of the
             procedure and provides signed informed consent form.

          -  Subject is willing to return to the investigational site for the 30- day and 6-month
             follow-up evaluations

        Exclusion Criteria:

          -  Subject who presents with ruptured aneurysm, unless rupture occured 30 days or more
             prior to screening.

          -  Subject who presents with an intracranial mass or currently undergoing radiation
             therapy for carcinoma of the head or neck region.

          -  Subject with an International Normalized Ratio (INR)≥ 1.5

          -  Subject with serum creatinine level &gt;2mg/dl at time of enrollment

          -  Subject with known allergies to nickel-titanium metal

          -  Subject with known allergies to aspirin, heparin, ticlopidine, or clopidogrel

          -  Subject with a life threatening allergy to contrast(unless treatment for allergy is
             tolerated)

          -  Subject who has a known cardiac disorder, likely to be associated with cardioembolic
             symptoms such as atrial fibrillation

          -  Subject with any condition which in the opinion of the treating physician would place
             the subject at a high risk of embolic stroke

          -  Subject who is currently participating in another clinical research study

          -  Subject who has had a previous intracranial stenting procedure associated with the
             target aneurysm

          -  Subject who is unable to complete the required follow-up

          -  Subject who is pregnant or breastfeeding

          -  Subject who has participated in a drug study within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Fiorella, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <results_first_submitted>September 5, 2014</results_first_submitted>
  <results_first_submitted_qc>September 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>September 6, 2014</last_update_submitted>
  <last_update_submitted_qc>September 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracranial aneurysm</keyword>
  <keyword>wide-neck</keyword>
  <keyword>saccular</keyword>
  <keyword>endovascular treatment</keyword>
  <keyword>coil embolization</keyword>
  <keyword>stent</keyword>
  <keyword>bare platinum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.): Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>excluded - metal allergy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>enrolled after study closed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>GI bleed prior to procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>stent not required</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>alternate stent used</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks)</title>
        <description>Imaging from each subject to be reviewed by an independent core lab who will be comparing with baseline and post procedure images.</description>
        <time_frame>6 months ± 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
          </group>
        </group_list>
        <measure>
          <title>Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks)</title>
          <description>Imaging from each subject to be reviewed by an independent core lab who will be comparing with baseline and post procedure images.</description>
          <units>percent occlusion of aneurysm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Measures as Any Major Stroke or Death Within 30 Days, or Major Ipsi-lateral Stroke or Neurological Death Within 6 Months</title>
        <description>A major stroke is defined as a new neurological event that persists for &gt;24 hours and results in a ≥ 4 point increase in the National Institutes of Health Stroke Scale (NIHSS) score compared to baseline or compared to any subsequent lower score.</description>
        <time_frame>30 days-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measures as Any Major Stroke or Death Within 30 Days, or Major Ipsi-lateral Stroke or Neurological Death Within 6 Months</title>
          <description>A major stroke is defined as a new neurological event that persists for &gt;24 hours and results in a ≥ 4 point increase in the National Institutes of Health Stroke Scale (NIHSS) score compared to baseline or compared to any subsequent lower score.</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parent Artery Patency Measured Angiographically at 6 Months</title>
        <description>To be assessed by Independent Core Lab.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Successful Delivery of the LVIS™ Device Measures by Technical Success</title>
        <description>Technical success being defined as: access to the lesion, successful deployment of the LVIS™ device.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Significant Stenosis(&gt;50%) of the Treated Artery at 6 Months</title>
        <description>Parent Artery will be measured baseline and compared at 6 months post procedure per review by the Independent Core Lab.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Migration at 6 Months</title>
        <description>Angiographic images will be comparing post procedure sent position to 6 months</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device and Procedure Related Serious Adverse Events</title>
        <description>All Serious Adverse events will be reported per protocol</description>
        <time_frame>Day 1-6months(± 4 months)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unplanned Embolization Coiling Within 6 Months</title>
        <description>If the target lesion(aneurysm)treated needed further embolization within 6 months of initial treatment(detected during follow up or unscheduled visit ),data will be recorded and analyzed.</description>
        <time_frame>Day 1-6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke/TIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hematoma at access site</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stroke or TIA</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>As part of a multi-center study the results of the national Trial shall be published by a National Principal Investigator within 12 months of completion of last study site. If no publication within that time frame, Principal Investigator is free to publish. Copies of proposed publication must be submitted to Sponsor at least 30 days in advance to ensure removal of proprietary or confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Schmitz</name_or_title>
      <organization>MicroVention, Inc.</organization>
      <phone>714-247-8025</phone>
      <email>mary.schmitz@microvention.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

